This multicenter, randomized, open-label phase 3 trial assessed the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab versus neoadjuvant chemotherapy alone in 391 patients with resectable locally advanced esophageal squamous cell carcinoma. The Cam+nab-TP and Cam+TP groups (camrelizumab with either albumin-bound paclitaxel and cisplatin or paclitaxel and cisplatin) showed significantly higher pathological complete response (PCR) rates (28.0% and 15.4%, respectively) than the TP group (4.7%). The safety profile was tolerable. Event-free survival data were not yet mature.
